Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
Paul M Wilkerson(University Hospitals Bristol NHS Foundation Trust), Jorge S. Reis‐Filho(AstraZeneca (France))
Cited by 15
Related Papers
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
|Science Translational Medicine|2011|401
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298